Dec. 7, 2004 (San Diego) — The combination of thalidomide and dexamethasone (thal/dex) is an effective induction therapy in patients with newly diagnosed multiple myeloma, according to investigators ...
MedPage Today on MSN
How to Treat Multiple Myeloma Patients With Renal Impairment
In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring ...
What is DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj)? DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines ...
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma Treatment of multiple myeloma ...
Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose-limiting ...
Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...
Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Multiple myeloma is a cancer that begins in ...
Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback